Skip to content

Savara SVRA Additional Paid-In Capital

Additional Paid-In Capital at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$682.09M+5.6%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$884.95M+27.4%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$1.16B+0.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$608.43M+14.6%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$141.53M+5.7%
TRV
Trevi Therapeutics, Inc.TRVI
$515.19M+29.9%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+134%
Enterprise value$1.19B+127%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's additional paid-in capital?
Savara (SVRA) reported additional paid-in capital of $821.64M in Q1 2026.
How has Savara's additional paid-in capital changed year-over-year?
Savara's additional paid-in capital increased by 23.7% year-over-year, from $664.2M to $821.64M.
What is the long-term trend for Savara's additional paid-in capital?
Over 5 years (2020 to 2025), Savara's additional paid-in capital has grown at a 20.4% compound annual growth rate (CAGR), from $320.89M to $811.1M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.